2021
Variations in Quality of Care by Sex and Social Determinants of Health Among Younger Adults With Acute Myocardial Infarction in the US and Canada
Raparelli V, Pilote L, Dang B, Behlouli H, Dziura JD, Bueno H, D’Onofrio G, Krumholz HM, Dreyer RP. Variations in Quality of Care by Sex and Social Determinants of Health Among Younger Adults With Acute Myocardial Infarction in the US and Canada. JAMA Network Open 2021, 4: e2128182. PMID: 34668947, PMCID: PMC8529414, DOI: 10.1001/jamanetworkopen.2021.28182.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionQuality of careHealth care systemYoung adultsFemale sexMyocardial infarctionCare systemHospital careSocial determinantsRetrospective cohort analysisLow qualityAdverse SDOHLowest tertileReadmission ratesMore patientsPostacute careAMI careOutpatient careCare scoresHigh prevalenceCohort analysisLarge cohortMAIN OUTCOMESDOHHospital
2020
Clinical Outcomes With Beta-Blocker Use in Patients With Recent History of Myocardial Infarction
Jackevicius CA, Krumholz HM, Ross JS, Koh M, Chong A, Austin PC, Stukel TA, Azizi P, Ko DT. Clinical Outcomes With Beta-Blocker Use in Patients With Recent History of Myocardial Infarction. Canadian Journal Of Cardiology 2020, 36: 1633-1640. PMID: 32416066, DOI: 10.1016/j.cjca.2020.01.024.Peer-Reviewed Original ResearchConceptsPrior myocardial infarctionMyocardial infarctionStable patientsPopulation-based observational studyAngina 1 yearDeath/hospitalizationHistory of revascularisationBeta-blocker useMajor cardiovascular eventsHospital discharge diagnosisUse of BBsIndividual end pointsContemporary clinical trialsYears of ageCardiovascular eventsIndex dateCohort studyComposite outcomeBB useHeart failureMedian agePrimary outcomeClinical outcomesAtrial fibrillationDischarge diagnosis
2019
Machine Learning Prediction of Mortality and Hospitalization in Heart Failure With Preserved Ejection Fraction
Angraal S, Mortazavi BJ, Gupta A, Khera R, Ahmad T, Desai NR, Jacoby DL, Masoudi FA, Spertus JA, Krumholz HM. Machine Learning Prediction of Mortality and Hospitalization in Heart Failure With Preserved Ejection Fraction. JACC Heart Failure 2019, 8: 12-21. PMID: 31606361, DOI: 10.1016/j.jchf.2019.06.013.Peer-Reviewed Original ResearchConceptsHF hospitalizationRisk of mortalityEjection fractionBlood urea nitrogen levelsLogistic regressionPrevious HF hospitalizationHeart failure hospitalizationReduced ejection fractionReceiver-operating characteristic curveRisk of deathBody mass indexBlood urea nitrogenUrea nitrogen levelsHealth status dataMean c-statisticKCCQ scoresTOPCAT trialFailure hospitalizationHeart failureHemoglobin levelsMass indexC-statisticHospitalizationUrea nitrogenMortality
2014
Impact of Drug Policy on Regional Trends in Ezetimibe Use
Lu L, Krumholz HM, Tu JV, Ross JS, Ko DT, Jackevicius CA. Impact of Drug Policy on Regional Trends in Ezetimibe Use. Circulation Cardiovascular Quality And Outcomes 2014, 7: 589-596. PMID: 24895451, PMCID: PMC4222175, DOI: 10.1161/circoutcomes.114.001023.Peer-Reviewed Original ResearchImpact of the ENHANCE Trial on the use of ezetimibe in the United States and Canada
Lu L, Krumholz HM, Tu JV, Ross JS, Ko DT, Jackevicius CA. Impact of the ENHANCE Trial on the use of ezetimibe in the United States and Canada. American Heart Journal 2014, 167: 683-689. PMID: 24766978, PMCID: PMC4215424, DOI: 10.1016/j.ahj.2014.01.014.Peer-Reviewed Original ResearchConceptsUse of ezetimibeENHANCE trialEzetimibe useProgression of atherosclerosisMain outcome measuresAtherosclerosis regression trialsMonthly numberOutcome measuresRegression trialsEzetimibeIMS HealthCommon evidence baseEvidence baseTrialsUnited StatesUtilization patternsFurther investigationDifferent utilization patternsPopulationDifferent patternsUse trendsAtherosclerosisSimvastatinProgression
2013
Urinary Biomarkers of AKI and Mortality 3 Years after Cardiac Surgery
Coca SG, Garg AX, Thiessen-Philbrook H, Koyner JL, Patel UD, Krumholz HM, Shlipak MG, Parikh CR. Urinary Biomarkers of AKI and Mortality 3 Years after Cardiac Surgery. Journal Of The American Society Of Nephrology 2013, 25: 1063-1071. PMID: 24357673, PMCID: PMC4005309, DOI: 10.1681/asn.2013070742.Peer-Reviewed Original ResearchConceptsKidney injury molecule-1Long-term mortalityIL-18Urinary biomarkersClinical AKICardiac surgeryHighest tertileUrinary neutrophil gelatinase-associated lipocalinProspective long-term followNeutrophil gelatinase-associated lipocalinContinuous net reclassification improvementInjury molecule-1Kidney injury biomarkersPostoperative day 1Gelatinase-associated lipocalinImmediate postoperative periodAdditional prognostic informationLong-term followNet reclassification improvementMortality 3 yearsLiver fatty acidAKI cohortCause mortalityHospital outcomesKidney injuryUse of Niacin in the United States and Canada
Jackevicius CA, Tu JV, Ko DT, de Leon N, Krumholz HM. Use of Niacin in the United States and Canada. JAMA Internal Medicine 2013, 173: 1379-1381. PMID: 23753308, DOI: 10.1001/jamainternmed.2013.6489.Peer-Reviewed Original Research
2012
Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies
Downing NS, Aminawung JA, Shah ND, Braunstein JB, Krumholz HM, Ross JS. Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies. New England Journal Of Medicine 2012, 366: 2284-2293. PMID: 22591257, PMCID: PMC3504361, DOI: 10.1056/nejmsa1200223.Peer-Reviewed Original ResearchConceptsNovel therapeutic agentsEuropean Medicines AgencyHealth CanadaTherapeutic agentsNew therapeutic agentsMedian lengthTherapeutic comparisonsDrug AdministrationMedicines AgencyNew drug applicationsPrescription Drug User Fee ActNovel therapeuticsDrug applicationFDAUnique agentUnited StatesTotal review timeFirst reviewRegulatory agenciesReview timeDaysAgentsReviewRegulatory reviewVast majority
2011
Use of Fibrates in the United States and Canada
Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM. Use of Fibrates in the United States and Canada. JAMA 2011, 305: 1217-1224. PMID: 21427374, PMCID: PMC3332101, DOI: 10.1001/jama.2011.353.Peer-Reviewed Original ResearchMeSH KeywordsCanadaCardiovascular DiseasesCohort StudiesCosts and Cost AnalysisDiabetes Mellitus, Type 2Drug CostsDrugs, GenericFenofibrateFibric AcidsHealth ExpendituresHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsMedical AuditPractice Patterns, Physicians'PrescriptionsUnited StatesConceptsUse of fibratesRole of fibratesObservational cohort studyIMS Health dataFenofibrate useCardiovascular riskCohort studyDiabetes (ACCORD) trialClinical benefitFibratesMonthsPrescriptionUnited StatesPatientsNegative resultsFenofibrateHealth dataCurrent useGeneric formulationPopulationStatinsTherapyTrials
2008
Use of Ezetimibe in the United States and Canada
Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of Ezetimibe in the United States and Canada. New England Journal Of Medicine 2008, 358: 1819-1828. PMID: 18375999, DOI: 10.1056/nejmsa0801461.Peer-Reviewed Original ResearchConceptsLipid-lowering agentsLow-density lipoprotein cholesterolLipid-lowering guidelinesRatio of prescriptionsUse of ezetimibeTreatment of hyperlipidemiaStatin useCohort studyLipoprotein cholesterolSecondary preventionStatin prescriptionClinical outcomesPrescribing practicesEzetimibeIMS HealthUnited StatesPrescriptionMonthly numberFirst optionDistinct patterns
2006
Regional Differences in Process of Care and Outcomes for Older Acute Myocardial Infarction Patients in the United States and Ontario, Canada
Ko DT, Krumholz HM, Wang Y, Foody JM, Masoudi FA, Havranek EP, You JJ, Alter DA, Stukel TA, Newman AM, Tu JV. Regional Differences in Process of Care and Outcomes for Older Acute Myocardial Infarction Patients in the United States and Ontario, Canada. Circulation 2006, 115: 196-203. PMID: 17190861, DOI: 10.1161/circulationaha.106.657601.Peer-Reviewed Original ResearchConceptsRisk-standardized mortality ratesTreatment patternsAMI patientsMortality rateOlder acute myocardial infarction patientsInvasive cardiac procedure useAcute myocardial infarction treatmentAcute myocardial infarction patientsBeta-blocker useCardiac catheterization useCardiac procedure useEnzyme inhibitor useMyocardial infarction patientsProcess of careService Medicare beneficiariesHealth care delivery systemSimilar treatment patternsMyocardial infarction treatmentCare delivery systemInvasive cardiac therapyBaseline characteristicsInhibitor useMedication useIllness severityRandomized trials
2005
Quality of Care and Outcomes of Older Patients With Heart Failure Hospitalized in the United States and Canada
Ko DT, Tu JV, Masoudi FA, Wang Y, Havranek EP, Rathore SS, Newman AM, Donovan LR, Lee DS, Foody JM, Krumholz HM. Quality of Care and Outcomes of Older Patients With Heart Failure Hospitalized in the United States and Canada. JAMA Internal Medicine 2005, 165: 2486-2492. PMID: 16314545, DOI: 10.1001/archinte.165.21.2486.Peer-Reviewed Original ResearchConceptsHeart failureProcess of careRisk-standardized mortalityQuality of careUS patientsMortality rateEnzyme inhibitorsLower crude mortality rateLower short-term mortalityAngiotensin-converting enzyme inhibitorRisk-standardized mortality ratesVentricular ejection fraction assessmentOutcomes of patientsShort-term mortalityUS Medicare beneficiariesIndividuals 65 yearsCrude mortality rateEjection fraction assessmentLow-risk characteristicsHealth care expendituresOlder patientsCanadian patientsCommon causeMedicare beneficiariesPatients